Although a Phase I/II clinical trial on the concurrent blockade of CD38 and PD-1 in solid-tumor cancers reported poor efficacy without significant anti-tumor activity, post-therapeutic examination revealed about a 40% reduction in the frequency of CD38+ tumor infiltrates in the TME and the reinvigoration of peripheral T-cell activity (34). This evidence concerns the gene CD38 and neoplasm.